R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
R1 Therapeutics has raised $77.5M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
R1 Therapeutics's investors include F-Prime, Curie.Bio, Abingworth, U.S. Renal Care, DaVita Venture Group.
R1 Therapeutics is headquartered in London, United Kingdom.
R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
R1 Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"R1 Therapeutics — Funding & Investors." VCBacked, March 17, 2026, https://www.vcbacked.co/company/r1-therapeutics. Accessed August 16, 2026.
VCBacked. (2026). R1 Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/r1-therapeutics
{{cite web |title=R1 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/r1-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated